These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 12012319)

  • 1. Expanding the use of arsenic trioxide: leukemias and beyond.
    Chen Z; Chen GQ; Shen ZX; Sun GL; Tong JH; Wang ZY; Chen SJ
    Semin Hematol; 2002 Apr; 39(2 Suppl 1):22-6. PubMed ID: 12012319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
    Slack JL; Waxman S; Tricot G; Tallman MS; Bloomfield CD
    Oncologist; 2002; 7 Suppl 1():1-13. PubMed ID: 11961204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug.
    Bonati A; Rizzoli V; Lunghi P
    Curr Pharm Biotechnol; 2006 Dec; 7(6):397-405. PubMed ID: 17168655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
    Liu P; Han ZC
    Int J Hematol; 2003 Jul; 78(1):32-9. PubMed ID: 12894848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.
    Zhou J; Zhang Y; Li J; Li X; Hou J; Zhao Y; Liu X; Han X; Hu L; Wang S; Zhao Y; Zhang Y; Fan S; Lv C; Li L; Zhu L
    Blood; 2010 Mar; 115(9):1697-702. PubMed ID: 20029047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
    Chou WC; Dang CV
    Curr Opin Hematol; 2005 Jan; 12(1):1-6. PubMed ID: 15604884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L; Mohassel L
    Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide: an ancient drug revived.
    Zhou J
    Chin Med J (Engl); 2012 Oct; 125(19):3556-60. PubMed ID: 23044323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide.
    Hirayama Y; Koyama R; Nagai T; Ohta H; Kondo A; Ishikawa K; Ishitani K; Matsunaga T; Sakamaki S; Niitsu Y
    Intern Med; 2001 Nov; 40(11):1136-9. PubMed ID: 11757771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Lengfelder E; Hofmann WK; Nowak D
    Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia.
    Soignet SL
    Oncologist; 2001; 6 Suppl 2():11-6. PubMed ID: 11331435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
    Xu SN; Chen JP; Liu JP; Xia Y
    Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular targets of arsenic trioxide in malignant cells.
    Miller WH
    Oncologist; 2002; 7 Suppl 1():14-9. PubMed ID: 11961205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy.
    Dombret H; Fenaux P; Soignet SL; Tallman MS
    Semin Hematol; 2002 Apr; 39(2 Suppl 1):8-13. PubMed ID: 12012316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.
    Torka P; Al Ustwani O; Wetzler M; Wang ES; Griffiths EA
    Blood Rev; 2016 May; 30(3):201-11. PubMed ID: 26709030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival.
    Chen Y; Gu L; Zhou C; Wu X; Gao J; Li Q; Zhu Y; Jia C; Ma Z
    Int J Hematol; 2010 May; 91(4):708-10. PubMed ID: 20405253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The optimal dose of arsenic trioxide induced opposite efficacy in autophagy between K562 cells and their initiating cells to eradicate human myelogenous leukemia.
    Guo Z; Meng M; Geng S; Du Z; Zheng Y; Yao J; Li Z; Han G; Lin H; Du G
    J Ethnopharmacol; 2017 Jan; 196():29-38. PubMed ID: 27965050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide.
    Litzow MR
    Expert Opin Pharmacother; 2008 Jul; 9(10):1773-85. PubMed ID: 18570609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide: mechanisms of action.
    Davison K; Mann KK; Miller WH
    Semin Hematol; 2002 Apr; 39(2 Suppl 1):3-7. PubMed ID: 12012315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.